What to Expect When You Start Tirzepatide

The myth: the starter pen is where results happen

People searching for how to start tirzepatide often expect the first injection to feel dramatic. It rarely does, and that is entirely by design. The 2.5mg starting dose exists to let your digestive system settle in. Nausea, reflux and loose stools are the most common early experiences, and keeping the starting dose low is the primary way the medicine's schedule tries to limit them. Your prescriber is the person who decides when to increase, the Patient Information Leaflet sets out the licensed schedule, but the timing of any step-up depends on how you are tolerating the current dose.

The therapeutic effect (reduced appetite, slower gastric emptying, changes in how your body processes calories) builds over time. Expecting significant weight loss in the first four weeks sets people up for disappointment and sometimes leads to unnecessary early stops. The SURMOUNT-1 trial, which tested tirzepatide in thousands of adults with obesity, ran for 72 weeks precisely because sustained treatment is what produces the outcomes shown in that evidence. Our Mounjaro overview covers the full trial picture in plain terms.

If you are already on treatment from another provider and want to continue, the process is a transfer rather than a restart, evidence of your current dose and duration is reviewed before any prescription is issued.

What actually changes when you start tirzepatide, and when

Within the first one to two weeks, many people notice their appetite is quieter. Meals feel filling sooner. The urge to snack between meals can diminish. These early changes are the GIP and GLP-1 receptor pathways doing what they are meant to: slowing how quickly the stomach empties and adjusting the signals that tell the brain the body has had enough. More on the early weeks of treatment explains what changes tend to appear first and what tends to come later.

Side effects, when they occur, are most common after starting treatment and again briefly after each dose increase. Nausea is the most frequently reported; diarrhoea and constipation both appear in the data. Most people find these settle within a week or two of each new dose. Eating smaller meals, staying hydrated and not lying down immediately after injecting can all help. If symptoms are severe or persistent, contact your prescriber, do not simply push through.

On injection days, your pen stays in the fridge until use. Tirzepatide comes as a pre-filled KwikPen; you inject into the abdomen, thigh or upper arm, rotating the site each week. The NHS tirzepatide medicines page has clear guidance on the injection technique alongside the full side-effect profile.

Who the licensed criteria cover (and what the prescriber weighs up

The UK licence for tirzepatide covers adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition) which can include high blood pressure, raised cholesterol, type 2 diabetes, obstructive sleep apnoea or prediabetes, among others. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A BMI figure alone, though, is not a prescription. A prescriber looks at the full picture: current health, other medicines, medical history, and whether tirzepatide is appropriate for you specifically.

Tirzepatide is not licensed for people under 18. It is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. Women taking oral contraceptive pills should add a barrier method for the first four weeks of treatment and for four weeks after any dose increase, because the pill's absorption may be reduced; guidance on starting Mounjaro covers this interaction in more detail. If you are considering HRT, your prescriber can advise on whether a transdermal form would be preferable.

The NICE appraisal of tirzepatide (TA1026) sets out the NHS eligibility criteria separately, they are more restrictive than the licensed criteria and are being phased in gradually. Private treatment through a regulated pharmacy, subject to clinical suitability, operates under the licensed criteria rather than the NHS phased thresholds. Thinking about the right time to start walks through some of the practical questions that come up at consultation.

How to start tirzepatide through a regulated UK service

Tirzepatide is a prescription-only medicine. The only legal route to it is a clinical assessment followed by a prescription from a registered prescriber, and that prescriber takes responsibility for your care. At some online pharmacies this happens the same day: you complete a consultation, a GPhC-registered Independent Prescriber reads your answers personally, and if the treatment is clinically appropriate, the prescription is issued. There is no algorithm making the decision.

Worth knowing before you start comparing services: some headline prices exclude the consultation, the prescription fee or aftercare support. The question to ask any provider is what happens if you have a side effect at 9pm on a Sunday. Our cost breakdown explains what a transparent price should include. Verifying a pharmacy on the GPhC register takes about thirty seconds and tells you whether it is legitimately registered, it is always worth doing. Pens ordered before 12pm on a working day, once clinically approved, are dispatched the same day and arrive by tracked DPD delivery the next working day in plain packaging.

If you are ready to find out whether tirzepatide is right for you, check your eligibility with our prescribers, the consultation is free, and there is no obligation.